Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

89.22EUR
10:09am EDT
Change (% chg)

€-0.31 (-0.35%)
Prev Close
€89.53
Open
€89.27
Day's High
€90.74
Day's Low
€88.12
Volume
3,394,762
Avg. Vol
3,245,940
52-wk High
€99.23
52-wk Low
€69.58

SASY.PA

Chart for SASY.PA

About

Sanofi is a healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. The Company is organized around three principal activities: Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. The Company invests in emerging markets,... (more)

Overall

Beta: 0.63
Market Cap(Mil.): €117,954.70
Shares Outstanding(Mil.): 1,317.53
Dividend: 2.85
Yield (%): 3.18

Financials

  SASY.PA Industry Sector
P/E (TTM): 27.63 35.73 39.36
EPS (TTM): 3.24 -- --
ROI: -- 17.15 16.35
ROE: -- 18.03 17.47
Search Stocks

UPDATE 1-New Sanofi CEO to unveil five-year plan in November -unions

PARIS, June 26 - Sanofi Chief Executive Olivier Brandicourt has told unions he will present a five-year strategic plan in November after the French company's third-quarter results, labour representatives said.

26 Jun 2015

Sanofi five-year plan to be unveiled in November -unions

PARIS, June 25 - Sanofi Chief Executive Olivier Brandicourt has told unions he will present a five-year strategic plan in November after the French company's third-quarter results, labour representatives said on Thursday.

25 Jun 2015

MOVES-Bertarelli's Waypoint hires ex-Sanofi CEO to lead health fund

June 23 - Waypoint Capital, the investment vehicle backed by biotech guru Ernesto Bertarelli, appointed former chief executive of Sanofi SA, Christopher Viehbacher, as a managing partner to its U.S.-based healthcare investment fund.

23 Jun 2015

Woodford exits bets on Sanofi, adds drug, tech firms

LONDON - Woodford Investment Management sold out of French pharmaceutical firm Sanofi in May on valuation grounds, the money manager said on Thursday, and instead added several smaller firms to its main fund.

11 Jun 2015

Woodford exits bets on Sanofi, adds drug, tech firms

LONDON, June 11 - Woodford Investment Management sold out of French pharmaceutical firm Sanofi in May on valuation grounds, the money manager said on Thursday, and instead added several smaller firms to its main fund.

11 Jun 2015

FDA panel backs Sanofi/Regeneron cholesterol drug with limits

(This version of the June 9th story corrects dosing schedule in last paragraph to every other week)

10 Jun 2015

CORRECTED-UPDATE 3-FDA panel backs Sanofi/Regeneron cholesterol drug with limits

June 10 - A new type of cholesterol-lowering drug made by Sanofi SA and Regeneron Pharmaceuticals should be approved, an advisory committee to the U.S. Food and Drug Administration concluded on Tuesday.

10 Jun 2015

UPDATE 2-FDA panel backs Sanofi/Regeneron cholesterol drug with limits

June 9 - A new type of cholesterol-lowering drug made by Sanofi SA and Regeneron Pharmaceuticals should be approved, an advisory committee to the U.S. Food and Drug Administration concluded on Tuesday.

09 Jun 2015

BRIEF-Zealand Pharma informs of updates given by Sanofi on Lyxumia and LixiLan

* Zealand informs of updates given by Sanofi on Lyxumia and LixiLan on an IR Thematic Conference Call on Diabetes

09 Jun 2015

No heart, other safety risks seen with Sanofi diabetes drug: study

- A large study demonstrated the heart safety of Sanofi's injectable type 2 diabetes drug lixisenatide and appears to rule out other potential health hazards as well, according to data presented at a medical meeting on Monday,

08 Jun 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$49.00
Provider: Finlabo SIM Spa
$10.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks